Cemiplimab in advanced cutaneous squamous cell carcinoma: the UK experience from the Named Patient Scheme
J Eur Acad Dermatol Venereol
.
2022 Jul;36(7):e590-e592.
doi: 10.1111/jdv.18082.
Epub 2022 Mar 24.
Authors
A Challapalli
1
,
S Watkins
2
,
G Cogill
3
,
G Stewart
4
,
S Ellis
5
,
A Sykes
6
,
J Nobes
7
,
K Yip
8
,
U Barthakur
9
,
R Board
10
,
A Gadve
11
,
L O'Toole
12
,
C Kent
13
,
J Mackenzie
14
,
S Papa
15
,
A Fusi
16
,
K Fife
17
Affiliations
1
University Hospitals Bristol & Weston NHS Foundation Trust, Bristol, UK.
2
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
3
University Hospitals Plymouth NHS Trust, Plymouth, UK.
4
Royal Cornwall Hospitals NHS Trust, Truro, UK.
5
Portsmouth Hospitals NHS Trust, Portsmouth, UK.
6
The Christie NHS Foundation Trust, Manchester, UK.
7
Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.
8
East Suffolk and North Essex NHS Foundation Trust, Colchester, UK.
9
Taunton and Somerset NHS Foundation Trust, Taunton, UK.
10
Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
11
NHS Greater Glasgow and Clyde, Glasgow, UK.
12
Hull University Teaching Hospitals NHS Trust, Hull, UK.
13
University Hospitals of Leicester NHS Trust, Leicester, UK.
14
NHS Lothian, Edinburgh, UK.
15
School of Cancer and Pharmaceutical Studies, King's College London, London, UK.
16
St George's University Hospitals NHS Foundation Trust, London, UK.
17
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
PMID:
35298050
DOI:
10.1111/jdv.18082
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Monoclonal, Humanized / therapeutic use
Carcinoma, Squamous Cell* / drug therapy
Humans
Skin Neoplasms* / drug therapy
United Kingdom
Substances
Antibodies, Monoclonal, Humanized
cemiplimab